Superluminal Medicines closed an oversubscribed $60 million Series B to advance its obesity program in the clinic. The company is developing next-generation small-molecule GPCR-targeted therapies for endocrine and cardiometabolic diseases, combining AI/machine learning, protein dynamics, and structural biology to work on challenging receptor biology. The funding positions Superluminal to generate Phase 1 data for a molecular approach aimed at competing in the increasingly crowded obesity space, where investors are looking for differentiation beyond efficacy—especially around safety, tolerability, and potential dosing convenience. As obesity development remains a high-capital priority, the oversubscribed nature of the round suggests investors see credible technical defensibility and development readiness in Superluminal’s GPCR strategy.